Study to Evaluate the Immunogenicity, Safety, and Tolerability of a Tick-Borne Encephalitis (TBE) Vaccine in Healthy Japanese Participants 1 Year of Age and Older

NCT04648241 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

165

Enrollment

INDUSTRY

Sponsor class

Conditions

Tick-Borne Encephalitis

Interventions

BIOLOGICAL: TBE vaccine 0.5 mL
BIOLOGICAL: TBE vaccine 0.25 mL

Sponsor

Pfizer